Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded use area of Klisyri to up to 100 cm 2 on the face and scalp for the treatment ...

Please provide your email address to receive an email when new articles are posted on . “As there is a risk of 0.025% to 16% per year for each actinic keratosis to progress to skin cancer, and it is ...

Background Actinic keratosis (AK) is a UV-induced, premalignant skin condition that is common in adults over 60 years of age with fair skin in Scotland. The most commonly prescribed first-line ...

Actinic keratosis (AK) is a common precancerous lesion arising from cumulative ultraviolet exposure, often heralding the development of non-melanoma skin cancers such as basal cell carcinoma and ...

BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...

EXTON, Pa., Dec. 15, 2020 /PRNewswire/ -- Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today that Klisyri® (tirbanibulin) has been approved by the U.S ...

Pharmacology: The mechanism of action by which ingenol mebutate induces cell death in treating actinic keratosis lesions is unknown. Clinical trials: In two double-blind, vehicle-controlled, clinical ...

We are fortunate to have treatment options to consider for individuals with multiple actinic keratoses. When counseling patients, however, their relative efficacy has been unclear, particularly for ...

A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient ...